Liquid Biopsy in Solid Tumor: An Ultimate Source for Molecular Landscaping, Biomarker Discovery and Clinical Management

Authors

  • Deep Kumari Yadav department of lifescience, gujarat university
  • Shayma Shaikh
  • Rakesh Rawal

DOI:

https://doi.org/10.37591/rrjooh.v8i3.1725

Keywords:

liquid biopsy, cell-free DNA, circulating tumor cell, exosomes, cancer management, biomarker

Abstract

Presently, work in the liquid biopsy field showed a great prospect utility in the diagnosis and stratification of cancer patients and furthermore personify an adaptive method for monitoring treatment response when compared to the tissue biopsy approach. Analysis of cell free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes, all conjointly referred to as “liquid biopsies,” are not only a modality to monitor treatment efficacy, disease progression, and emerging therapy resistance mechanisms, but they also assess tumor heterogeneity and evolution in real-time. This review concerned the different isolation, detection approaches, their role in cancer management and future outlook on the use of liquid biopsy in biomarker discovery. These biomarkers not only have prognostic values but also can help to lodge treatment decisions by monitoring tumor burden, detecting minimal residual disease or recurrent disease, as well as monitoring evolution of genetic alterations throughout the treatment course.

 

Keywords: cancer management, cell-free DNA (cfDNA), circulating tumor cell (CTC), exosomes, liquid biopsy

 

Cite this Article

Deep Kumari Yadav, Shayma Shaikh, Rakesh Rawal. Liquid biopsy in solid tumor: An ultimate source for molecular landscaping, biomarker discovery and clinical management. Research & Reviews: Journal of Oncology and Hematology. 2019; 8(3): 25–36p.

Downloads

Published

2019-12-16

Issue

Vol. 8 No. 3 (2019)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.